» Articles » PMID: 30082852

Narrowing the Gap for Hematopoietic Stem Cell Transplantation in the East-Mediterranean/African Region: Comparison with Global HSCT Indications and Trends

Abstract

Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006-2013. Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the worldwide 71.036 HSCT, and a transplant rate of 32.8 (TR; HSCT/10 million inhabitants; worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006. HSCT activity in AFR/EMRO countries was characterized by a higher use of allogeneic compared to autologous HSCT, an almost exclusive use of family donors, including haploidentical family donors. These findings contrast with the prevalence of autologous over allogeneic HSCT, and a higher frequency of unrelated HSCT in other parts of the world. Of note, the increase by 200% in HSCT for hemoglobinopathies from 2006 to 2013 (72 per year) in the AFR/EMRO region. This reflects the specific role of HSCT for these disease categories with high prevalence and incidence in the AFR/EMRO region. This report provides information for the competent authorities to foster adequate infrastructure. It urges transplant organization to optimize their cooperation.

Citing Articles

Transfusions, disease-modifying treatments, and curative therapies for sickle cell anemia in Africa: where are we now?.

Odame I, Bazuaye G Hematology Am Soc Hematol Educ Program. 2024; 2024(1):234-239.

PMID: 39643983 PMC: 11665607. DOI: 10.1182/hematology.2024000550.


Medical Tourism for Cancer Treatment: Trends, Trajectories, and Perspectives From African Countries.

Rubagumya F, Carson L, Afolayan D, Rugengamanzi E, Nnko G, Abdihamid O JCO Glob Oncol. 2024; 10:e2400131.

PMID: 39447099 PMC: 11529831. DOI: 10.1200/GO.24.00131.


Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases.

Maqbool S, Baloch M, Khan M, Khalid A, Naimat K World J Transplant. 2024; 14(1):87532.

PMID: 38576761 PMC: 10989471. DOI: 10.5500/wjt.v14.i1.87532.


A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: framework and case studies.

Saleh S, Dabbous O, Sullivan S, Ankleshwaria D, Trombini D, Toumi M Gene Ther. 2023; 31(1-2):1-11.

PMID: 37903929 PMC: 10788266. DOI: 10.1038/s41434-023-00425-x.


The perception of pediatric sickle cell anemia patient's caregivers toward hematopoietic stem cell transplantation (single-center experience, Saudi Arabia).

Monagel D, Alemam N, Betar M, Alnafisi F, Faidah D, Aloteibi R Front Pediatr. 2023; 11:1205351.

PMID: 37287628 PMC: 10242087. DOI: 10.3389/fped.2023.1205351.


References
1.
. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation. 2010; 90(3):229-33. DOI: 10.1097/TP.0b013e3181ec29f0. View

2.
Thomas E, Storb R, Clift R, Fefer A, Johnson L, Neiman P . Bone-marrow transplantation (second of two parts). N Engl J Med. 1975; 292(17):895-902. DOI: 10.1056/NEJM197504242921706. View

3.
Jaimovich G, Rolon J, Baldomero H, Rivas M, Hanesman I, Bouzas L . Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplant. 2017; 52(5):671-677. DOI: 10.1038/bmt.2016.361. View

4.
Aljurf M, Zaidi S, Hussain F, Ghavamzadeh A, Alimoghaddam K, Jahani M . Status of hematopoietic stem cell transplantation in the WHO Eastern Mediterranean Region (EMRO). Transfus Apher Sci. 2010; 42(2):169-75. DOI: 10.1016/j.transci.2010.01.012. View

5.
Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P . Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015; 50(4):476-82. PMC: 4387247. DOI: 10.1038/bmt.2014.312. View